Climb Bio to present new Phase 1b budoprutug data in immune thrombocytopenia at ASH
CLYM•Climb Bio will present preliminary Phase 1b budoprutug data in previously treated adults with primary immune thrombocytopenia at the American Society of Hematology meeting on Dec. 13, 2026.
1. Presentation details
The ongoing trial evaluates the anti-CD19 antibody in previously treated adults with primary immune thrombocytopenia. The presentation will cover safety, B-cell depletion and platelet data across all three dose cohorts.
